
JPGN Journal Club September 2026 Paediatric: MASLD, Liver Fibrosis and Risk of Type 2 Diabetes
Jake has chosen for today’s session two studies in metabolic dysfunction-associated steatotic liver disease – for convenience, henceforward “MASLD”. I’ve added three.
Jake’s choices . . . Well. One addresses the question: Can MASLD scoring identify children at high risk of developing Type II diabetes?
(Spoiler alert: Yes. Kinda sorta.)
The other presents the ESPGHAN consensus on MASLD: What, who, when, where, and why. (Authorial alert: Jake’s implicated as, Lord preserve us, senior author, although all co-authors are eminently respectable.)
And my additions? The MASLD-scoring article depends…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.